MindMed’s Phase 2 LSD Trial Treating Anxiety Was a Success
Researchers at PSYCH Symposium reveal promising results from double-blind, placebo-controlled study with 46 patients.
Author: James Hallifax
Why Wednesday Will Be Biggest Day of 2022 for Psychedelic Investors
Psychedelic investors are about to see pivotal data presented on flagship programs by the titans of the psychedelics industry.
Wesana Health May Sell Clinics to Focus Solely on Drug Development: An Analysis
Wesana Health reaches a major strategic pivot point. Our resident Psychedelic Investor examines what this means for the company and industry at large.
Fungus Among Us: 5 Fascinating Facts About Mushrooms
Science just keeps discovering how cool and beneficial mushrooms are, with or without psilocybin.
Elon Musk Excites Psychedelic Industry CEOs with This Tweet
This is one of the billionaire’s most explicit acknowledgments of the power of psychedelics for mental health applications.
Why Field Trip Health Is Dividing in Two — and What This Means for Investors
Field Trip Health plans to split into two independent, publicly traded companies: Field Trip Health and Wellness and Reunion Neuroscience.
MAPS Navigates Multiple Scandals: Why Health Canada Is Reviewing MDMA Trials
A sexual misconduct scandal, a data scandal, and an elder abuse scandal haunt psychedelics leader MAPS, currently being scrutinized by Health Canada.
Understanding 3 Risks of Investing in Psychedelic Stocks
No one is responsible for your financial future, other than yourself, so be responsible with your money.
Kevin O’Leary Predicts These 3 Psychedelic Companies Will Merge, But Should They?
Our resident Psychedelic Investor James Hallifax wonders if the “Shark Tank” star’s prediction makes financial sense.
5 Examples of Ancient Psychedelic Cave Art
Ancient civilizations have been using psychedelic substances, like psilocybin, for millenniums, and the proof is in their cave art.
End of content
End of content